Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 68.2827
- Book/Share 31.2062
- PB 9.8739
- Debt/Equity 0.857
- CurrentRatio 0.7386
- ROIC 0.3875
- MktCap 1475022984970.3071
- FreeCF/Share 16.8361
- PFCF 19.7343
- PE 13.0759
- Debt/Assets 0.2427
- DivYield 0.0342
- ROE 0.8124
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
| Upgrade | NVO | Kepler | Hold | Buy | -- | -- | March 13, 2025 |
| Downgrade | NVO | Stifel | Buy | Hold | -- | -- | March 3, 2025 |
| Initiation | NVO | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVO | Bernstein | Underperform | Market Perform | -- | -- | Jan. 6, 2025 |
News
Novo Nordisk cuts 2025 guidance on weaker-than-expected Wegovy sales, posts first-quarter profit beat
Published: May 07, 2025 by: CNBC
Sentiment: Negative
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Read More
Obesity drugmaker Novo Nordisk cuts 2025 outlook, posts Q1 profit above forecast
Published: May 07, 2025 by: Reuters
Sentiment: Neutral
Obesity drugmaker Novo Nordisk on Wednesday posted first-quarter operating profit above analyst forecasts and cut its operating profit and sales outlook for the year.
Read More
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
7 May 2025 - Financial report for the period 1 January 2025 to 31 March 2025
Read More
Pharma sector still investable, faces added headwinds, says BMO's Siegerman
Published: May 06, 2025 by: CNBC Television
Sentiment: Neutral
Evan Siegerman, BMO Capital Markets, joins 'Fast Money' to talk new headwinds facing the pharma sector.
Read More
Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share.
Published: May 06, 2025 by: Barrons
Sentiment: Negative
Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has brought stumbles for Novo over the past year.
Read More
Why Novo Nordisk (NVO) is a Top Momentum Stock for the Long-Term
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 6 May 2025 – Novo Nordisk today announced that new data spanning the company's industry-leading portfolio across metabolic and cardiovascular health will be presented at the upcoming 32nd European Congress on Obesity (ECO), 11–14 May 2025. The data will further extend the wide-ranging evidence base for semaglutide through real-world evidence studies and additional analysis of the landmark cardiovascular outcomes trial, SELECT, as well as part 1 of the phase 3 ESSENCE trial in metabolic dysfunction-associated steatohepatitis (MASH). Data will also be presented on the wider societal impacts of treating and preventing obesity, alongside analysis of the burden of …
Read More
HIMS Earnings Ahead: Wegovy Offers Upside, Analysts Advise Caution
Published: May 05, 2025 by: Schwab Network
Sentiment: Neutral
"There's a sense of caution" heading into Hims & Hers (HIMS) earnings, says Caroline Woods. The telehealth company is up over 65% so far in 2025 but has fallen more than 40% off its February highs.
Read More
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Read More
Novo Nordisk: FDA Accepts New Drug Application for Oral Wegovy
Published: May 02, 2025 by: WSJ
Sentiment: Positive
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a GLP-1 drug for chronic weight management.
Read More
U.S. FDA accepts Novo Nordisk's application for oral Wegovy
Published: May 02, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for the experimental once-daily oral version of its blockbuster weight-loss drug Wegovy, the Danish drugmaker said on Friday.
Read More
Why Is Novo Nordisk Stock Trading Higher On Friday?
Published: May 02, 2025 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S' NVO Canada unit on Thursday announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg, a once-weekly therapy for people living with MASH (metabolic dysfunction-associated steatohepatitis).
Read More
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
Published: May 02, 2025 by: The Motley Fool
Sentiment: Positive
Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that China may be "evaluating the possibility of starting trade negotiations" that could abbreviate a trade war with the U.S.
Read More
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment
Published: May 01, 2025 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S NVO announced that CVS Health Inc's CVS CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy (semaglutide) injection 2.4 mg will soon be the preferred GLP-1 medicine on its largest commercial template formularies.
Read More
Why Novo Nordisk Stock Popped Today
Published: May 01, 2025 by: The Motley Fool
Sentiment: Positive
Novo Nordisk (NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m.
Read More
CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
Published: May 01, 2025 by: CNBC
Sentiment: Positive
CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Under a new partnership between Caremark and Wegovy's manufacturer, Novo Nordisk, CVS will make the drug available to its members at "a more affordable price.
Read More
Novo Nordisk: The Fear Is Overblown
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk's about 55% stock decline since June 2024 is driven by clinical trial misses, increasing competition, and geopolitical turbulence. Due to the compressed valuation, Novo Nordisk needs to grow in the mid-single digit range to justify the current valuation. Considering realistic growth rates, the company could be undervalued by 50+%.
Read More
Hims & Hers stock price soars after partnership with Novo Nordisk to offer weight-loss drug Wegovy
Published: April 30, 2025 by: Fast Company
Sentiment: Positive
Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordisk. That partnership will see Hims & Hers offer Novo Nordisk's weight-loss drug Wegovy through its platform.
Read More
Why New Wegovy Deals Won't Restore Novo Nordisk's Obesity Lead
Published: April 30, 2025 by: WSJ
Sentiment: Negative
The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only getting wider.
Read More
Growth Is Priced Out Of Novo Nordisk
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Negative
A lot went wrong for Novo Nordisk A/S in the last six months, and a lot went right for competitor Eli Lilly. Novo Nordisk's competitive positioning in the obesity market has worsened, but I believe the market has overshot to the downside. Not all is lost, and there are additional efforts the company is making to stay relevant, ranging from new trials of CagriSema and higher doses of semaglutide, to external innovation.
Read More
Hims & Hers stock pops on Novo Nordisk partnership
Published: April 29, 2025 by: Proactive Investors
Sentiment: Positive
Hims & Hers (NYSE:HIMS) shares surged after it announced a partnership with Novo Nordisk that will allow it to offer the drugmaker's weight loss product Wegovy through its telehealth platform. Investors welcomed the collaboration, which positions Hims & Hers to participate directly in the fast-growing market for GLP-1 weight-loss drugs.
Read More
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Published: April 29, 2025 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S NVO and Hims & Hers Health, Inc. HIMS announced a long-term collaboration on Tuesday.
Read More
Pharma firms maastraz
Published: April 29, 2025 by: CNBC International TV
Sentiment: Neutral
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
Read More
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
Read More
Hims & Hers partners with Novo Nordisk to sell Wegovy
Published: April 29, 2025 by: Fox Business
Sentiment: Positive
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Read More
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price. The deal is a game changer, enabling Hims to offer Wegovy at $599/month versus $1,999/month. I think this deal hints at potential to do the same with Ozempic further boosting the stock, which is already up +30% in pre-market trading.
Read More
White House Slams AMZN, HIMS & NVO Wegovy Partnership, SOFI Rallies
Published: April 29, 2025 by: Schwab Network
Sentiment: Negative
Amazon (AMZN) shares faced selling pressure after the White House called the company's decision to display tariff costs on products a "hostile and political act." Diane King Hall notes it's just the latest company following a formula.
Read More
Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar
Published: April 29, 2025 by: WSJ
Sentiment: Positive
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.
Read More
Novo Nordisk's obesity drug Wegovy debuts in Thailand
Published: April 28, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's local subsidiary said on Monday, marking the injectable drug's first entry into the Southeast Asian market.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406